Here's how NATURE.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NATURE . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Nature.com Make Money
  6. How Much Does Nature.com Make
  7. Keywords
  8. Topics
  9. Questions
  10. Schema
  11. Social Networks
  12. External Links
  13. Analytics And Tracking
  14. Libraries
  15. Hosting Providers

We are analyzing https://www.nature.com/articles/4401649.

Title:
Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1 | Cell Death & Differentiation
Description:
Clinical trials have been initiated with Apo2L/TRAIL (Genentech) and agonistic mAbs to TRAIL receptors, -R1 and -R2 (Human Genome Sciences). The apoptosis-inducing ability of these mAbs and different TRAIL preparations, in the presence or absence of histone deacetylase inhibitors (HDACi), varied markedly against primary chronic lymphocytic leukaemia (CLL) cells and various tumor cell lines, demonstrating an unanticipated preferential apoptotic signaling via either TRAIL-R1 or -R2. Contrary to literature reports that TRAIL-induced apoptosis occurs primarily via signaling through TRAIL-R2, CLL cells, in the presence of HDACi, undergo predominantly TRAIL-R1-mediated apoptosis. Consequently, Apo2L/TRAIL, which signals primarily through TRAIL-R2, is virtually devoid of activity against CLL cells. To maximize therapeutic benefit, it is essential to ascertain whether a primary tumor signals via TRAIL-R1/-R2, prior to initiating therapy. Thus combination of an agonistic TRAIL-R1 Ab and an HDACi, such as the anticonvulsant sodium valproate, could be of value in treating CLL.
Website Age:
30 years and 10 months (reg. 1994-08-11).

Matching Content Categories {📚}

  • Science
  • Education
  • Health & Fitness

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌆 Monumental Traffic: 20M - 50M visitors per month


Based on our best estimate, this website will receive around 42,554,915 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}


Display Ads {🎯}


The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {💰}


Display Ads {🎯}

$536,300 per month
According to our algorithms, Nature.com's monthly online income from display advertising ranges from $357,503 to $983,134.

Keywords {🔍}

cells, apoptosis, trailr, trail, cll, article, cell, figure, google, scholar, cas, apoltrail, hgsetr, depsipeptide, caspase, patients, valproate, ngml, hdaci, trailinduced, trailhisle, death, signaling, surface, trailhis, expression, receptor, agonistic, receptors, data, human, preparations, ligand, clinical, tumor, cancer, nature, lymphocytic, mabs, primary, processing, chronic, shown, sensitization, primarily, activity, leukemia, forms, results, lines,

Topics {✒️}

nature portfolio permissions reprints tnf-related apoptosis-inducing ligand privacy policy epstein–barr virus-negative burkitt' nature 364 nature related apoptosis-inducing ligand tumour-necrosis factor superfamily advertising tumour necrosis factor histone deacetylase inhibitors related b-cell malignancies death-inducing signaling complex b-cell prolymphocytic leukemia chronic lymphocytic leukaemia development chronic lymphocytic leukemia isotype-matched control antibody conjugated mouse anti-dr4 anti-trail receptor antibodies social media regulate agonist-specific mechanisms materials media death receptor-induced apoptosis author correspondence expresses primarily trail-r1 adaptor molecule fadd/mort1 tumor cell lines permissions express surface trail-r2 histone deacetylase trail-r1 decreased markedly potentiating trail-induced-apoptosis potentiated trail-induced apoptosis primary tumor signals cell surface trail-r2 temperature-sensitive differential affinity cytotoxic ligand trail trail-r1-selective variants primary tumor cells apo2l/trail signals primarily recombinant apo2l/trail versions apoptosis-inducing ability sensitize tumor cells agonistic trail-r1 ab anti-fas antibody distinct caspase cascades cell death differ trail-r2 increased markedly

Questions {❓}

  • Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1
         description:Clinical trials have been initiated with Apo2L/TRAIL (Genentech) and agonistic mAbs to TRAIL receptors, -R1 and -R2 (Human Genome Sciences). The apoptosis-inducing ability of these mAbs and different TRAIL preparations, in the presence or absence of histone deacetylase inhibitors (HDACi), varied markedly against primary chronic lymphocytic leukaemia (CLL) cells and various tumor cell lines, demonstrating an unanticipated preferential apoptotic signaling via either TRAIL-R1 or -R2. Contrary to literature reports that TRAIL-induced apoptosis occurs primarily via signaling through TRAIL-R2, CLL cells, in the presence of HDACi, undergo predominantly TRAIL-R1-mediated apoptosis. Consequently, Apo2L/TRAIL, which signals primarily through TRAIL-R2, is virtually devoid of activity against CLL cells. To maximize therapeutic benefit, it is essential to ascertain whether a primary tumor signals via TRAIL-R1/-R2, prior to initiating therapy. Thus combination of an agonistic TRAIL-R1 Ab and an HDACi, such as the anticonvulsant sodium valproate, could be of value in treating CLL.
         datePublished:2005-04-29T00:00:00Z
         dateModified:2005-04-29T00:00:00Z
         pageStart:773
         pageEnd:782
         sameAs:https://doi.org/10.1038/sj.cdd.4401649
         keywords:
            chronic lymphocytic leukaemia
            tumor necrosis factor-apoptosis inducing ligand
            TRAIL-R1
            histone deacetylase inhibitors
            Life Sciences
            general
            Biochemistry
            Cell Biology
            Stem Cells
            Apoptosis
            Cell Cycle Analysis
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.cdd.4401649/MediaObjects/41418_2005_Article_BF4401649_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.cdd.4401649/MediaObjects/41418_2005_Article_BF4401649_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.cdd.4401649/MediaObjects/41418_2005_Article_BF4401649_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.cdd.4401649/MediaObjects/41418_2005_Article_BF4401649_Fig4_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.cdd.4401649/MediaObjects/41418_2005_Article_BF4401649_Fig5_HTML.jpg
         isPartOf:
            name:Cell Death & Differentiation
            issn:
               1476-5403
               1350-9047
            volumeNumber:12
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:M MacFarlane
               affiliation:
                     name:University of Leicester
                     address:
                        name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S Inoue
               affiliation:
                     name:University of Leicester
                     address:
                        name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S L Kohlhaas
               affiliation:
                     name:University of Leicester
                     address:
                        name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A Majid
               affiliation:
                     name:University of Leicester
                     address:
                        name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:N Harper
               affiliation:
                     name:University of Leicester
                     address:
                        name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:D B J Kennedy
               affiliation:
                     name:University of Leicester, Leicester Royal Infirmary
                     address:
                        name:Department of Hematology, University of Leicester, Leicester Royal Infirmary, Leicester, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M J S Dyer
               affiliation:
                     name:University of Leicester
                     address:
                        name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
                        type:PostalAddress
                     type:Organization
                     name:University of Leicester, Leicester Royal Infirmary
                     address:
                        name:Department of Hematology, University of Leicester, Leicester Royal Infirmary, Leicester, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:G M Cohen
               affiliation:
                     name:University of Leicester
                     address:
                        name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1
      description:Clinical trials have been initiated with Apo2L/TRAIL (Genentech) and agonistic mAbs to TRAIL receptors, -R1 and -R2 (Human Genome Sciences). The apoptosis-inducing ability of these mAbs and different TRAIL preparations, in the presence or absence of histone deacetylase inhibitors (HDACi), varied markedly against primary chronic lymphocytic leukaemia (CLL) cells and various tumor cell lines, demonstrating an unanticipated preferential apoptotic signaling via either TRAIL-R1 or -R2. Contrary to literature reports that TRAIL-induced apoptosis occurs primarily via signaling through TRAIL-R2, CLL cells, in the presence of HDACi, undergo predominantly TRAIL-R1-mediated apoptosis. Consequently, Apo2L/TRAIL, which signals primarily through TRAIL-R2, is virtually devoid of activity against CLL cells. To maximize therapeutic benefit, it is essential to ascertain whether a primary tumor signals via TRAIL-R1/-R2, prior to initiating therapy. Thus combination of an agonistic TRAIL-R1 Ab and an HDACi, such as the anticonvulsant sodium valproate, could be of value in treating CLL.
      datePublished:2005-04-29T00:00:00Z
      dateModified:2005-04-29T00:00:00Z
      pageStart:773
      pageEnd:782
      sameAs:https://doi.org/10.1038/sj.cdd.4401649
      keywords:
         chronic lymphocytic leukaemia
         tumor necrosis factor-apoptosis inducing ligand
         TRAIL-R1
         histone deacetylase inhibitors
         Life Sciences
         general
         Biochemistry
         Cell Biology
         Stem Cells
         Apoptosis
         Cell Cycle Analysis
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.cdd.4401649/MediaObjects/41418_2005_Article_BF4401649_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.cdd.4401649/MediaObjects/41418_2005_Article_BF4401649_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.cdd.4401649/MediaObjects/41418_2005_Article_BF4401649_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.cdd.4401649/MediaObjects/41418_2005_Article_BF4401649_Fig4_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fsj.cdd.4401649/MediaObjects/41418_2005_Article_BF4401649_Fig5_HTML.jpg
      isPartOf:
         name:Cell Death & Differentiation
         issn:
            1476-5403
            1350-9047
         volumeNumber:12
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:M MacFarlane
            affiliation:
                  name:University of Leicester
                  address:
                     name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S Inoue
            affiliation:
                  name:University of Leicester
                  address:
                     name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S L Kohlhaas
            affiliation:
                  name:University of Leicester
                  address:
                     name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A Majid
            affiliation:
                  name:University of Leicester
                  address:
                     name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:N Harper
            affiliation:
                  name:University of Leicester
                  address:
                     name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:D B J Kennedy
            affiliation:
                  name:University of Leicester, Leicester Royal Infirmary
                  address:
                     name:Department of Hematology, University of Leicester, Leicester Royal Infirmary, Leicester, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M J S Dyer
            affiliation:
                  name:University of Leicester
                  address:
                     name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
                     type:PostalAddress
                  type:Organization
                  name:University of Leicester, Leicester Royal Infirmary
                  address:
                     name:Department of Hematology, University of Leicester, Leicester Royal Infirmary, Leicester, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:G M Cohen
            affiliation:
                  name:University of Leicester
                  address:
                     name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Cell Death & Differentiation
      issn:
         1476-5403
         1350-9047
      volumeNumber:12
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Leicester
      address:
         name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
         type:PostalAddress
      name:University of Leicester
      address:
         name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
         type:PostalAddress
      name:University of Leicester
      address:
         name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
         type:PostalAddress
      name:University of Leicester
      address:
         name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
         type:PostalAddress
      name:University of Leicester
      address:
         name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
         type:PostalAddress
      name:University of Leicester, Leicester Royal Infirmary
      address:
         name:Department of Hematology, University of Leicester, Leicester Royal Infirmary, Leicester, UK
         type:PostalAddress
      name:University of Leicester
      address:
         name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
         type:PostalAddress
      name:University of Leicester, Leicester Royal Infirmary
      address:
         name:Department of Hematology, University of Leicester, Leicester Royal Infirmary, Leicester, UK
         type:PostalAddress
      name:University of Leicester
      address:
         name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:M MacFarlane
      affiliation:
            name:University of Leicester
            address:
               name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
               type:PostalAddress
            type:Organization
      name:S Inoue
      affiliation:
            name:University of Leicester
            address:
               name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
               type:PostalAddress
            type:Organization
      name:S L Kohlhaas
      affiliation:
            name:University of Leicester
            address:
               name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
               type:PostalAddress
            type:Organization
      name:A Majid
      affiliation:
            name:University of Leicester
            address:
               name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
               type:PostalAddress
            type:Organization
      name:N Harper
      affiliation:
            name:University of Leicester
            address:
               name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
               type:PostalAddress
            type:Organization
      name:D B J Kennedy
      affiliation:
            name:University of Leicester, Leicester Royal Infirmary
            address:
               name:Department of Hematology, University of Leicester, Leicester Royal Infirmary, Leicester, UK
               type:PostalAddress
            type:Organization
      name:M J S Dyer
      affiliation:
            name:University of Leicester
            address:
               name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
               type:PostalAddress
            type:Organization
            name:University of Leicester, Leicester Royal Infirmary
            address:
               name:Department of Hematology, University of Leicester, Leicester Royal Infirmary, Leicester, UK
               type:PostalAddress
            type:Organization
      name:G M Cohen
      affiliation:
            name:University of Leicester
            address:
               name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
      name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
      name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
      name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
      name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
      name:Department of Hematology, University of Leicester, Leicester Royal Infirmary, Leicester, UK
      name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK
      name:Department of Hematology, University of Leicester, Leicester Royal Infirmary, Leicester, UK
      name:MRC Toxicology Unit, Hodgkin Building, University of Leicester, Leicester, UK

Social Networks {👍}(1)

External Links {🔗}(123)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mxa-002c5801.gslb.pphosted.com
  • mxb-002c5801.gslb.pphosted.com

Name Servers:

  • pdns1.ultradns.net
  • pdns2.ultradns.net
  • pdns3.ultradns.org
  • pdns4.ultradns.org
  • pdns5.ultradns.info
  • pdns6.ultradns.co.uk
5.53s.